Publicacións nas que colabora con Moisés Rodríguez Mañero (122)

2026

  1. Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System

    International Journal of Clinical Pharmacy

  2. External validation of atrial fibrillation risk scores in heart failure under continuous device surveillance

    Heart Rhythm

  3. Left ventricular ejection fraction determines the pattern of left atrial remodeling in patients with heart failure without atrial fibrillation

    Clinical Research in Cardiology

2025

  1. Carvedilol versus flecainide treatment in idiopathic ventricular extrasystoles and tachycardias (CARFLECT IV) trial: Rationale and design

    Revista Portuguesa de Cardiologia, Vol. 44, Núm. 12, pp. 709-715

  2. Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study

    Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 19, Núm. 9

  3. Epigenetic regulation of electromechanical continuity might determine phenotypic heterogeneity in SCN5A mutation carriers in Brugada syndrome

    Scientific Reports, Vol. 15, Núm. 1

  4. Plasma small extracellular vesicles: Markers and mediators of atrial scar, in patients with atrial fibrillation

    Heart Rhythm, Vol. 22, Núm. 12, pp. 3257-3267

  5. Prevalence and relevance of H558R in the efficacy and toxicity of flecainide in patients with atrial fibrillation: a cohort study

    Heart, Vol. 111, Núm. 4, pp. 159-165

  6. Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients With Atrial Fibrillation:. Cohort Study

    Journal of Cardiovascular Pharmacology, Vol. 86, Núm. 4, pp. 384-390

  7. Simplified 3-ganglionated plexus ablation for the treatment of recurrent vasovagal syncope and functional bradyarrhythmia

    Heart Rhythm

  8. Single-chamber pacemakers: with or without leads? Cost-effectiveness and cost-utility analyses

    Annals of Medicine, Vol. 57, Núm. 1

2024

  1. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

    Diseases, Vol. 12, Núm. 10

  2. Effect of age on clinical impact and mid-term denervation in patients undergoing cardioneuroablation

    Scientific Reports, Vol. 14, Núm. 1

  3. Enhanced Levels of Adiposity, Stretch and Fibrosis Markers in Patients with Coexistent Heart Failure and Atrial Fibrillation

    Journal of Cardiovascular Translational Research, Vol. 17, Núm. 1, pp. 13-23

  4. Enhancing patient outcomes: Integrating electronic cardiology consultation in primary care for cancer patients

    European Journal of Clinical Investigation, Vol. 54, Núm. 8

  5. Impact of a clinician-to-clinician electronic consultation in heart failure patients with previous hospital admissions

    European Heart Journal - Digital Health, Vol. 5, Núm. 1, pp. 9-20

  6. Pseudotransposition of the great leads

    PACE - Pacing and Clinical Electrophysiology, Vol. 47, Núm. 2, pp. 233-235

  7. Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers

    International Journal of Molecular Sciences, Vol. 25, Núm. 22

2023

  1. Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study

    ESC Heart Failure, Vol. 10, Núm. 5, pp. 3055-3066

  2. Characterization of Atrial Substrate to Predict the Success of Pulmonary Vein Isolation: The Prospective, Multicenter MASH-AF II (Multipolar Atrial Substrate High Density Mapping in Atrial Fibrillation) Study

    Journal of the American Heart Association, Vol. 12, Núm. 1, pp. e027795